VEGFA and hepatocellular carcinoma: Therefore, whilst we envisage that macrophage/TAM-based therapies will be at the forefront of the emergence of the next wave of immunotherapy technologies for the treatment of HCC, they are likely be utilised in conjunction with existing treatments, such as immune checkpoint blockade and anti-VEGF therapies, to significantly boost the efficacy of these approaches.